PharmaCielo Cannabis Co. Sees 390% YoY Revenue Jump As Losses Narrow In Q2 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 16 2024
0mins
Source: Benzinga
Financial Performance: PharmaCielo Ltd reported a 390% increase in revenue year-over-year for Q2 2024, totaling CA$783,680, while net loss narrowed to CA$2.58 million compared to CA$3.6 million in Q2 2023.
CEO Insights: CEO Marc Lustig highlighted the company's strategic position in the emerging cannabis market, emphasizing reduced operating expenses and improved adjusted EBITDA, which reflects their focus on high-margin products and profitability.
Analyst Views on PCLO
Wall Street analysts forecast PCLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCLO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 24.925
Low
Averages
High
Current: 24.925
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
